Published Research

Treatment of asthma with lipid extract of New Zealand green-lipped mussel (PCSO-524™): a randomised clinical trial


ABSTRACT: Asthma is a chronic inflammatory disease of the airways mediated, at least in part, by leukotrienes and other lipid mediators. Experimental studies have shown that lipid extract of New Zealand green-lipped mussel (PCSO-524™), *Perna canaliculus*, is effective in inhibiting 59-lipoxygenase and cyclo-oxygenase pathways responsible for production of eicosanoids, including leukotrienes and prostaglandins. The aim of this study was to assess its effect on symptoms, peak expiratory flow (PEF) and hydrogen peroxide (H2O2) in expired breath condensate as a marker of airway inflammation in patients with steroid-naive atopic asthma in a double-blind randomised, placebo-controlled clinical trial.

Forty-six patients with atopic asthma received two capsules of lipid extract (PCSO-524™) or placebo b.i.d. for 8 weeks. Each capsule of lipid extract contained 50 mg v-3 polyunsaturated fatty acids and 100 mg olive oil, whereas placebo capsules contained only 150 mg olive oil.

There was a significant decrease in daytime wheeze, the concentration of exhaled H2O2 and an increase in morning PEF in the lipid extract group compared to the placebo group. There were no significant side effects.

The authors conclude that lipid extract of New Zealand green-lipped mussel (PCSO-524™) may have some beneficial effect in patients with atopic asthma. Eur Respir J 2002; 20: 596–600.

Efficacy and tolerability of Green Lipped mussel extract –PCSO-524™ omega-3-complex on inflammatory rheumatoid disorders

Joerg Gruenwald, Ph.D.1 Hans-Joachim Graubaum, Ph.D. 1 Knuth Hansen, M.D.2 Barbara Grube, M.D. 2 PhytoPharm Research, a unit of analyze & realize, Berlin (Germany) 2 Private Surgery Kurfuerstendamm, Berlin (Germany)

ABSTRACT

This 12 week drug monitoring study evaluated the effects of Sanhelios mussel-PCS0-524™ omega-3-complex, on 50 adult men and women suffering from inflammatory rheumatoid arthritis. 34 of the 50 patients required medicinal treatment before and during the study. Upon completion of the study, for 21 of the 34 subjects (64 %) current drug therapy could be reduced or terminated. 13 of those did not even require further therapy. At the end of the treatment period, 38 % of all subjects were regarded as being free from disorders and the number of subjects suffering from severe pain was significantly decreased from 60% (at baseline) to 25 % (at completion of the trial). A significant positive effect was observed for all investigated parameters. Sanhelios mussel- PCS0-524™ omega-3-complex was generally very well tolerated, with only one, non-serious adverse
event (mild nausea) observed, which can probably be related to the study medication. Sanhelios mussel- PCSO-524™ omega-3-complex, therefore, proved to be an effective and very well tolerated dietary supplement for the treatment of inflammatory rheumatoid arthritis.

Clinical Efficacy and Safety of Patented Extract from New Zealand Green Lipped Mussel (*Perna Canaliculus*) (PCSO-524™) in Patients with Osteoarthritis of the Hip and Knee: Multicenter Clinical Trial with a 2 Months Treatment Period

Se Haeng Cho M.D. *, Young Bok Jung Hyung, Bin Park Dong, Chunl Lee Jung Hwan Son M.D. 1, M.D. 3 M.D. 5, M.D. 7, Sang Chul Sung Ki Yong Byeun Eun Kyoo Song M.D. 2, M.D. 4, M.D. 6,

• Yonsei Medical Clinic, 2, Seoul National University, 4, Chungnam University 6, Chonnam University

1, Department of Orthopedic Surgery, Chung Ang University; 3, Kyung Sang University; 5, Youngnam University 7, Kosin University

Abstract

**Objective:** To validate the clinical efficacy and safety of a patented extract from *Perna Canaliculus* (PCSO-524™), a LOX inhibitor in patients with osteoarthritis.

**Methods:** In this multicenter trial, 54 patients with symptomatic osteoarthritis of the knee and hip were to receive PCSO-524™ at a dose of 2 capsules twice a day. After 4 and 8 weeks treatment period, the following parameters were analyzed; Visual analogue scale, Lequesne index, Global assessment by patients, Global assessment by doctors and adverse effects.

**Results:** PCSO-524™ treatment led to significant improvement in the signs and symptoms of osteoarthritis as determined by all efficacy measures. After 4 and 8 weeks treatment period, 53% and 80% of patients experienced significant pain relief and improvement of joint function. There was no proven adverse effect during this clinical trial.

**Conclusion:** PCSO-524™ was very effective and promised anti-inflammatory material to relieve the signs and symptoms of osteoarthritis without adverse effect.

Treatment of knee osteoarthritis with lipid extract of the green-lipped mussel PCSO-524™ – a double-blind placebo-controlled study

LAU CS1, CHIU PKY2, CHU EMY1, CHENG IYW2, TANG WM2, MAN RYK3, HALPERN GM4
Summary

Treatment of osteoarthritis (OA) includes pain control and improvement of patients’ function and quality of life. While conventional treatment such as non-steroidal anti-inflammatory drugs and simple analgesics may achieve these goals, their use is not without side effects. The use of “natural remedies” and “folklore medicines” is therefore commonly practiced by patients with OA. PCSO-524™ is a lipid extract of the green-lipped mussel, which is rich in omega-3 fatty acids and has previously been shown to have anti-inflammatory effects in both in vitro and animal studies. The aim of this study was to compare the effects of PCSO-524™ with placebo on the signs and symptoms and patient quality of life in the treatment of knee OA. Eighty patients with knee OA were randomized to receive either PCSO-524™ or placebo for six months. All were allowed paracetamol rescue treatment during the study and were reviewed at week 0, 2, 4, 8, 12, 18 and 24 for arthritis assessment and safety evaluation. Assessment of the patients’ arthritis included the use of a 100 mm visual analog scale (VAS) for pain, patient’s and physician’s global assessment of arthritis, a validated Chinese version of the Oxford Knee Score (COKS), a validated Chinese version of the Arthritis Impact Measurement Scale 2-short form (CAIMS2-SF), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Improvement in almost all of the arthritis assessment parameters was observed in both groups of patients studied. However, there was a greater improvement in the perception of pain as measured by the VAS, and patients’ global assessment of arthritis in those who took PCSO-524™ when compared with controls from week 4 following adjustment for the change in the amount of paracetamol used between study visits. Patients who took PCSO-524™ but not placebo also had improved scores in the CAIMS2-SF physical function and psychological status domains from week 4. However, changes in these scores did not differ significantly between the two groups at various study visits. When used over six months, PCSO-524™ was safe and well tolerated with no serious side effects reported. Further, there were no significant differences in the overall incidence of adverse reactions or withdrawal from study as a result of trial drug toxicity between PCSO-524™ and placebo treated patients. In conclusion, PCSO-524™, a lipid extract of the green-lipped mussel, may be considered a safe option in the treatment of OA.

The CO2-SFE crude lipid extract and the free fatty acid extract from Perna canaliculus (PCSO-524™) have anti-inflammatory effects on adjuvant-induced arthritis in rats

M. Singh a, L.D. Hodges a, P.F.A. Wright b, D.M.Y. Cheah b, P.M. Wynne c

N. Kalafatis a, T.A. Macrides a,⁎

A Natural Products Research Group, School of Medical Sciences, RMIT University, Bundoora, Victoria, 3083, Australia a Key Centre for Toxicology, School of Medical Sciences, RMIT University, Bundoora, Victoria, 3083, Australia b SGE International Pty Ltd, Ringwood, Victoria, 3134, Australia c

Received 23 August 2007; received in revised form 18 September 2007; accepted 19 September 2007 Available online 26 September 2007

The anti-inflammatory (AI) activity of a supercritical fluid extract (CO2-SFE) of tartaric acid-stabilised Perna canaliculus mussel powder, and of the free fatty
acid (FFA) class separated from the CO2-SFE extract (PCSO-524™) by column chromatography, was investigated in the rat adjuvant arthritis model. Administration of the CO2-SFE extract (100 mg/kg BW/day s.c.) for 15 days post-adjuvant inoculation significantly reduced rear paw swelling by 34% and the deterioration in total body condition by 52% in arthritic rats, compared to vehicle controls. These observations were accompanied by a decreased serum ceruloplasmin oxidase activity, and reduced inflammatory response of the spleen. The mussel FFA extract given at one third of the dose (30 mg/kg BW/day s.c.) and for a shorter treatment period (5 days during the inflammatory phase) achieved an even greater AI activity, and was equipotent to piroxicam (2 mg/kg BW/day s.c.). Preliminary toxicology assessment using both arthritic and non-arthritic (healthy) rats revealed no significant differences between the mussel treatment groups and respective vehicle controls in either organ weights, tissue histology or selected biochemical parameters. These results indicate the CO2-SFE crude lipid extract (PCSO-524™) and its FFA components from stabilised P. canaliculus mussel powder contain biologically significant AI activity in vivo, with no apparent adverse side effects. © 2007 Elsevier Inc. All rights reserved.

Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel (*Perna canaliculus*) (PCSO-524™)

S. McPhee a, L.D. Hodges a, P.F.A. Wright b, P.M. Wynne c, N. Kalafatis a, D.W. Harney a, T.A. Macrides a,

a Natural Products Research Group, School of Medical Sciences, Division of Laboratory Medicine, RMIT University, PO Box 71, Bundoora, Victoria 3083, Australia
b Toxicology Key Centre, School of Medical Sciences, School of Medical Sciences, RMIT University, Bundoora, Victoria, 3083, Australia
c SGE International Pty Ltd., Ringwood, Victoria, Australia

Received 27 June 2006; received in revised form 13 November 2006; accepted 14 November 2006 Available online 17 November 2006

**Abstract**

Total lipid extracts of *P. canaliculus*, (PCSO-524™) (a bivalve marine mollusc native to New Zealand, commonly called the green-lipped mussel) and *Mytilus edulis* (commonly called the common blue mussel) moderately inhibited ovine COX-1 and COX-2 pure enzymes in vitro. The inhibition was increased after the PCSO-524™ was saponified by KOH hydrolysis. Protease- and protease–lipase-hydrolysed lipid extracts of *P. canaliculus* exhibited similarly strong COX inhibition as the KOH-hydrolysed extract. PCSO-524™ (a commercial extract from *P. canaliculus*) also exhibited strong inhibition of both COX isoforms, an effect that was increased 10-fold upon subsequent hydrolysis. In contrast, fish oil was not as anti-COX active as PCSO-524™. The PCSO-524™ free fatty acid fraction, and to a lesser extent the PCSO-524™ triglyceride fraction, were the only lipid classes of PCSO-524™ to exhibit strong inhibition of the COX isoforms. The purified PUFA extracts were all bioactive, potently inhibiting COX-1 and COX-2. Incubation of PCSO-524™ in the absence of exogenous arachidonic acid (AA) showed the appearance of alternate prostaglandin metabolites, confirming
PCS0-524™ PUFA as a competitive substrate inhibitor of AA metabolism. © 2006 Elsevier Inc. All rights reserved.

Novel anti-inflammatory ω-3 PUFAs from the New Zealand green-lipped mussel, *Perna canaliculus* (PCS0-524™)

A.P. Treschow a, L.D. Hodges a, P.F.A. Wright b, P.M. Wynne c, N. Kalafatis a, T.A. Macrides a,

a Natural Products Research Group, School of Medical Sciences, RMIT University, Bundoora, Victoria, 3083, Australia
b Applied and Nutritional Toxicology Key Centre, School of Medical Sciences, RMIT University, Bundoora, Victoria, 3083, Australia
c SGE International Pty Ltd, Ringwood, Victoria, 3134, Australia

Received 21 December 2006; received in revised form 5 April 2007; accepted 5 April 2007 Available online 14 April 2007

The present study has identified in the marine mollusc, *Perna canaliculus*, an homologous series of novel omega 3 polyunsaturated fatty acids (ω-3 PUFA) with significant anti-inflammatory (AI) activity. The free fatty acid (FFA) class was isolated from a supercritical-CO2 lipid extract of the tartaric acid-stabilised freeze-dried mussel powder by normal phase chromatography, followed by reversed-phase high performance liquid chromatography (RP–HPLC). The RP–HPLC involved separation based on carbon numbers, followed by argentation–HPLC (Ag–HPLC) of the methyl esters based on degree of unsaturation. Identification of the FFA components was performed using gas chromatography (GC) with flame ionisation detection, and individual structures were assigned by GC–mass spectroscopy (GC–MS). Inhibition of leukotriene production by stimulated human neutrophils was used as an in vitro screening method to test the AI activity of the purified PUFAs. A structurally related family of ω-3 PUFAs was identified in the most bioactive fractions, which included C18:4, C19:4, C20:4, and C21:5 PUFA. The C20:4 were the predominant PUFA in the extract, and were a structural isomer of arachidonic acid (AA). The novel compounds may be biologically significant as AI agents, as a result of their in vitro inhibition of lipoxygenase products of the AA pathway. © 2007 Elsevier Inc. All rights reserved.

PCSO-524™: a potential preventive treatment for inflammatory bowel disease (IBD)

1D Tenikoff, 2KJ Murphy, 1M Le, 1RN Butler, 1GS Howarth, 2PRC Howe
1Child Health Research Institute, Women’s & Children’s Hospital, SA 5006
2Nutritional Physiology Research Group, University of Adelaide and University of South Australia, SA 5005

Background: Fish oil and the stabilised lipid extract of New Zealand Green Lipped Mussel (PCSO-524™; LYP) are considered beneficial in treating arthritis and other inflammatory conditions. Unlike fish oil, it is uncertain whether any benefit seen with LYP is due to its omega-3 (ω3) fatty acid content. We compared the effect of LYP and fish oil pre-treatments on experimental induction of IBD in mice.
Methods - Male C57BL/6 mice aged 6 weeks were gavaged daily for 13 days with 150μl of olive oil (OO, n=7), LYP (5mg in OO; n=8) or fish oil (FO, 55mg EPA/DHA; n=8). Mice consumed 2% dextran sulfate sodium (DSS) for 6 days from day 7 to induce colitis. Body weight and disease activity index (DAI) scores were recorded daily; colonic inflammation was assessed by myeloperoxidase (MPO) activity and histopathologic damage to the ileum and colon.

Results - FO treatment had no significant benefit compared with OO. By day 12 of the trial, OO treated mice had gained 15±2% body weight, FO treated mice had gained 6±5% (significantly lower than LYP and OO P<0.05) and LYP treated mice had gained 21±3% (significantly higher than FO P<0.05): LYP treated mice had a lower DAI score (0 vs. 1 for OO, 4 for FO). Compared with FO, LYP treated mice had smaller crypt area losses (distal colon), lower caecum and colon weights and a trend for lower overall colitis severity in the distal colon. MPO activity was not significantly affected by either LYP or FO vs. OO (see table).

Conclusions - These findings indicate that LYP may be potentially useful in ameliorating symptoms of IBD. The lack of effect of FO indicates that the benefit of LYP is attributable to components of the stabilised lipid extract other than its ω3 content. A dose-response evaluation of LYP in experimental IBD is warranted.

PCSO-524™ (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease

Danik Tenikoff1,3, Karen J. Murphy3,5, Maria Le5, Peter R. Howe3,5, and Gordon S. Howarth1,2,3,4,5,6

1 Child Health Research Institute, Women’s and Children's Hospital, North Adelaide, South Australia, Australia 2 Gastroenterology Department, Women’s and Children’s Hospital, 72 King William Road, North Adelaide, SA 5006, Australia 3 Discipline of Physiology, The University of Adelaide, Adelaide, South Australia, Australia 4 Discipline of Paediatrics, The University of Adelaide, South Australia, Australia 5 School of Pharmaceutical, Molecular and Biomedical Sciences, The University of South Australia, Adelaide, South Australia, Australia 6 School of Biological, Sciences, Flinders University Bedford Park, Adelaide, South Australia, Australia

Background. PCSO-524™ (Pharmalink International), the stabilised lipid extract of the New Zealand green-lipped mussel, is currently used to relieve symptoms of arthritis. We investigated the effect of pretreatment with PCSO-524™ (LYP) on experimentally induced inflammatory bowel disease (IBD) in mice. Methods. Male C57BL/6 mice (aged 6 weeks) were gavaged daily for 13 days with (150 μl) olive oil (OO; n = 7), fish oil (FO; n = 8), or LYP (n = 8). Mice consumed 2% dextran sulfate sodium (DSS) for 6 days, starting on day 7. Body weight and disease activity index (DAI) scores were recorded daily. Colonic damage was determined by histopathology. Colonic inflammation was quantified by myeloperoxidase (MPO) activity. Results. LYP treatment significantly (P < 0.05) reduced body weight loss, DAI scores, crypt area losses, and cecum and colon weights, compared with FO treatment. MPO activity was not significantly affected by any treatment. Conclusions. These findings provide preliminary evidence that PCSO-524™ may be potentially useful in ameliorating symptoms of
IBD. The benefit, however, is unlikely to be due to the omega-3 fatty acid content. Dose-response evaluation of PCSO-524™ in experimental IBD is warranted.

**Pain Controlling and Cytokine-regulating Effects of PCSO-524™, a Lipid Extract of *Perna canaliculus*, in a Rat Adjuvant-induced Arthritis Model**

Chi-Ho Lee1, John Hon-Kei Lum1, Curtise Kin-Cheung Ng2, Janice McKay2, Yoki Kwok-Chu Butt1, Man-Sau Wong1 and Samuel Chun-Lap Lo1

1State Key Laboratory of Chinese Medicine and Molecular Pharmacology, Shenzhen and Department of Applied Biology and Chemical Technology and 2Department of Health Technology and Informatics, Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China

Using an adjuvant-induced arthritis rat model, we investigated the effects of a lipid extract of *Perna canaliculus* PCSO-524™ on pain. Radiological examinations, as well as levels of pro- and anti-inflammatory (AI) cytokines, were measured aiming to provide independent objective data to the pain controlling investigation. We confirmed the ability of PCSO-524™ to control pain at the initial phase of its administration; with similar efficacy to that observed with Naproxen. The pain scores slowly increased again in the group of rats treated with PCSO-524™ after day 9–14. The Naproxen-treated rats remained pain-free while treated. Both Naproxen and PCSO-524™ decreased the levels of the pro-inflammatory cytokines TNF-α and IFN-γ, and increased that of IL-10. Extra-virgin olive oil was ineffective on cytokine secretion. Rats treated with PCSO-524™ were apparently cured after 1 year. This study confirms the AI efficacy of this lipid extract of *P. canaliculus*, its initial analgesic effect, its perfect tolerance and its long-term healing properties.


Christopher J. Wolyniak, J. Thomas Brenna, Karen J. Murphyb, and Andrew J. Sinclairc,*

aDivision of Nutritional Sciences, Savage Hall, Cornell University, Ithaca, New York, bChild Health Research Institute, Bedford Park, South Australia 5042, Australia, and cDepartment of Food Science, RMIT University, Melbourne, Victoria 3001, Australia

**ABSTRACT:** Supercritical fluid extracts of New Zealand green-lipped mussels (PCSO-524™) have been suggested to have therapeutic properties related to their oil components. The large number of minor FA in NZGLM extract was characterized by a GC–CIMS/MS method that excels at identification of double-bond positions in FAME. The extract contained five major lipid classes: sterol esters, TAG, FFA, sterols, and polar lipids. The total FA content of the lipid extract was 0.664 g/mL. Fifty-three unsaturated FA (UFA) were fully identified, of which 26 were PUFA, and a further 21 UFA were detected for which concentrations were too low for assignment of double-bond positions. There were 17 saturated FA, with 14:0, 16:0, and 18:0 present in the greatest concentration. The ten n-3 PUFA detected included 20:5n-3 and 22:6n-3, the two main n-3 FA; n-3 PUFA at low concentration were 18:3, 18:4, 20:3, 20:4, 21:5, 22:5, 24:6, and 28:8. There were 43 UFA from the n-4, n-5, n-6, n-7, n-9, and n-10 families, with 16:2n-4,
16:1n-5, 18:1n-5, 18:2n-6, 20:4n-6, 16:1n-7, 20:1n-7, 16:1n-9, 18:1n-9, and 20:1n-9 being the most abundant. In general, we estimated that FAME concentrations greater than 0.05% (w/w) were sufficient to asign double-bond position. In total, 91 FA were detected in an extract of the NZGLM, whereas previous studies of fresh flesh from the NZGLM had reported identification of 42 FA. These data demonstrate a remarkable diversity of NZGLM FA.

**Gastroprotective and anti-inflammatory properties of green lipped mussel (Perna canaliculus) preparation.**

Rainsford KD, Whitehouse MW.
Freeze-dried powdered preparations of whole (i.e. without shell) green-lipped mussel (Perna canaliculus) from New Zealand given orally to rats showed some modest anti-inflammatory activity (carrageenan paw oedema). This material strikingly reduced the gastric ulcerogenicity of several non-steroid anti-inflammatory drugs in rats and pigs. The gastroprotective activity in rats was primarily associated with particular lipid fractions, which exhibited differential protective activity against acetylsalicylic acid on the one hand and indometacin on the other.

PMID: 7194074 [PubMed - indexed for MEDLINE]

**Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they?**

M. W. WHITEHOUSE 1 *, M. S. ROBERTS 1 and P. M. BROOKS 2
1 Department of Medicine, University of Queensland, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia 2 Executive Dean (Health Sciences). University of Queensland, Royal Brisbane Hospital, Herston, Queensland 4029, Australia

Received 15 February 1999; revised 30 March 1999; accepted 1 April 1999

Abstract—**Background:** Increasingly patients resort to alternative remedies for arthritis and rheumatism, perhaps partly impelled by reports of toxicities from prescribed non-steroid anti-inflammatory drugs (NSAID). There is uncertainty about whether the most common alternative treatments provide relief or may cause adverse reactions.

**Aim:** To ascertain the validity of manufacturers’ claims permitted by the Therapeutic Goods Administration (TGA) in Australia for a range of self-medication products to treat the pain and inflammation of arthritis, available in local pharmacies, supermarkets or by mail order and in other countries.

**Methods:** OTC products were administered orally to rats in standard assays for suppressing experimental arthritis and fever and for determining potential gastrotoxicity.

**Results:** The three NSAIDs available OTC were efficacious but gastrotoxic. Of the 37 herbal formulations examined, seven were as effective as ibuprofen in the anti-arthritic assay without causing gastric bleeding. Five of the 10 animalsourced products tested were also effective without evident toxicity. Within a
certain class of product, e.g. celery seed extracts or dried mussel preparations, efficacies ranged from almost zero to highly effective.

Conclusions: Consumers currently have no guide to the likely efficacy of TGA-approved remedies. Quality control is urgently needed to justify the veracity of TGA-permitted and other claims on product labels.

LIPID FRACTION OF NEW ZEALAND GREEN LIPPED MUSSEL (PCSO-524™) INHIBITS LTB PRODUCTION BY HUMAN MONOCYTES.

B. Dugas(1)

Summary
The effect of PCSO-524™ was evaluated on LTB4-induced human monocytes (normal and allergic donors) Activation. Peripheral blood normal monocyte-derived monocytes when stimulated by Interleukin-4 (IL-4) produced high amounts of leukotriene B4 (LTB4) through the activation of the 5-Lipoxygenase Pathway. Maximal effect was observed in the presence of 10ng/ml IL-4, and maximal LTB4 production was reached 40 min after the onset of stimulation. When stimulated for 48 h with IL-4, Resting human monocytes expressed and released the low affinity receptor for IgE (CD23), and were inhibited in the presence of PCSO-524™, or of the non redox 5-lipoxygenase inhibitor (BWB70C), suggesting that the production of LTB4 partially contributed to the IL-4-induced CD23 Expression and release. In addition to these Phenotypical changes, IL-4 Primed the phorbo-12-myristate-13 acetate (PMA)-induced luminol-dependent chemiluminescence response (LDCL) by normal human monocytes; this priming effect was abrogated in the presence of PCSO-524™, or BW B70C. Monocyte-derived monocytes from allergic patients spontaneously produced high amounts of LTB4, expressed CD23 expression, and had an increased oxidative metabolism. In the presence of PCSO-524™, or of a BW B70C, the hyper-activation of monocytes from allergic patients was significantly suppressed. Taken together, these data indicated that the pharmacological control of the 5-lipoxygenase pathway in human monocytes can be achieved with regulate the expression and release of CD23 and the respiratory burst of human monocytes.

The treatment of arthritis with a lipid extract of perna canaliculus PCSO-524™: a randomized trail

S.L.M. Gibson, R.G. Gibson, Glasgow Homoeopathic Hospital Glasgow, UK

SUMMARY. Objective: to assess the efficacy of lipid extract of the New Zealand green-lipped mussel, Perna canaliculus (PCSO-524™) in rheumatoid and osteoarthritis ad compare it with green-lipped muscle powder. Design: A double – blind 3 month parallel comparison of the two preparations and a further 3-month period on lipid extract for all patients Setting: The out-patient department of the Glasgow Homoeopathic Hospital. Interventions; Stabilized green-lipped mussel powder, 1150 mg/day and the derived lipid extract, 210 mg/day. Main Outcome Measures: Articular index of joint tenderness (AI), morning stiffness (limbering-up-time, LUT), grip strength in each hand, visual analogue scale of pain (VA) and functional index (FI). Results: Seventy six percent of rheumatoid and 70% of osteoarthritis patients benefitted. AI, LUT and FI improved
significantly by 3 months. The two preparations appeared equally efficacious. One patient experienced fluid retention and one developed nausea. There were no other adverse reactions. Conclusion: Both the stabilized freeze-dried mussel powder and its derived lipid extract are effective in the reducing pain, swelling and stiffness and in improving functional index in rheumatoid arthritis and osteoarthritis.

The Effect of a Lipid Extract of the New Zealand Green-Lipped Mussel (PCSO-524™) in Three Cases of Arthritis

SHEILA L.M. GIBSON., M.D., B.Sc., M.F.HOM.

INTRODUCTION
Extracts of the New Zealand green-lipped mussel, perna canaliculus, have been used since the 1980s for the treatment of both rheumatoid arthritis and osteoarthritis. A pilot study suggested that this could be helpful and a double-blind placebo-controlled trial found the mollusk to be effective for 68% of patients with rheumatoid arthritis and for 40% of those with osteoarthritis (Gibson, et al., 1980). Not all researchers, however, obtained similar beneficial results (Caughey, et al., 1983; Huskisson, et al., 1981; Larkin, et al., 1980s that stabilization of the product was necessary to maintain biologic activity. More recently, a lipid extract has been developed and has proved to be indistinguishable in its activity of thus preparation is in the lipid fraction rather than in the protein moiety (Gibson and Gibson, 1998). In the comparative study of the lipid fraction versus the stabilized mussel powder (Gibson and Gibson, 1998), statistically significant improvements were observed in patients with both rheumatoid arthritis and osteoarthritis within 1 month of starting treatment, but there was no obvious overall difference between the two preparations. Seventy-five percent of patients with both rheumatoid arthritis and osteoarthritis benefitted. Although the number of patients in the trail was small (60 in total; 30 with rheumatoid arthritis and 30 with osteoarthritis), some patients, particularly those with rheumatoid arthritis, seemed to respond remarkably quickly to the lipid extract as illustrated by the following three case studies. These three patients was monitored by means of the articular index (AI) of joint pain (Ritchie, et al., 1968), Limbering up time (LUT) or morning stiffness, grip strength in each hand (Lee, et al., 1973), which are the answers to a series of 22 questions that assess each patient’s ability to turn the head, bend, use the hands and arms, and walk and climb up and down stairs. The values obtained for these parameters for the three patients at the first consultation and after 2 months, are given in Table 1.

The Anti-inflammatory Effects of omega Tetraenoic Fatty Acids Isolated from a Lipid Extract from the mussel, Perna canaliculus (PCSO-524™)
T.A Macrides, Perna canaliculus. T.A. Macrides(1), A.P. Treschow(1), N. Kalafati(1), P.F.A. Wright(1), P.M. Wynne(2)
The lipid extracts of Perna canaliculus (PCSO-524™), the green-lipped mussel of New Zealand, have been shown to have anti-inflammatory activity (AI) and the greatest activity is shown by the polyunsaturated free fatty acid (PUFA) class(1). We have identified a homologous series of novel omega PUFA’s with significant AI activity in an in vitro leukotriene inhibition assay. The proportion of novel PUFAs in the crude lipid extract was 0.12%w/w and in the total mussel material, 0.005%w/w. The total free FAs were isolated from a supercritical-CO(2) lipid extract of the freeze-dried mussel powder by flash chromatography, followed by reversed-phase HPLC. This technique involved a separation based on carbon number, followed by Ag-HPLC of the of the methyl esters based on the degree of unsaturation. Identification of FA components was performed using GLC with flame ionisation detection and individual structure were assigned from the pyrrolidide derivatives by GC-MS. Inhibition of leukotriene B(4) (LTB4) produced from stimulated human neutrophils was used as an in vitro screening method to test the efficacy of purified PUFAs for AI activity. The two most active fractions obtained from the separations inhibited LTB(4) formation by 64% and 47% respectively (at 1:100 dilution). A structurally related family of Omega free fatty acids was indentified in the most bioactive fraction which included C18:4, C19:4 and C20:4 PUFAs. Two C20:0Omega3 structural analogue of arachidonic acid have been synthesised for testing in an in vivo adjuvant-induced polyarthritis model 1. T.A. Macrides and N. Kalafatis (1995) Int. Patent PCT/AU 95/004/85.

Lipid, FA, and Sterol Composition of New Zealand Green Lipped Mussel (Perna canaliculus) and Tasmanian Blue Mussel (Mytilus edulis)

Karen J. Murphy(a)*, Ben D. Mooney(b), Neil J. Mann(a), Peter D. Nichols(b), and Andrew J. Sinclair(a) 'RMIT University, Melbourne Vicotria, 3001, Australia, and (b)CSIRO Marine Research, Hobart. Tasmania 7001, Australia

Abstract: The lipid FA, and sterol composition of the New Zealand green lipped mussel (NZGLM), Perna canaliculus) and of the Tasmanian blue mussel (TBM, Mytilus edulis) were compared using TLC-FID and GC-MS. The respective mussel species were obtained from three different sites in both New Zealand (NZ) and Tasmania, Lipid class distribution of both mussel species was characterized by a high proportion of phospholipid (PL, 57-79%) and TG (10-25%), FFA (7-12%) and sterols (ST, 12-18%). The NZGLM had higher Proportions of TG, FFA and ST (P<0.01), where as the TBM had a higher proportion of PL (P<0.01). There were higher proportions of total PUFA, saturated FA, n-3 FA, in the NZGLM were 16:0 (15-17%) 20:5n-3 (14-20%), and 22:6n-3 (11-17%). The same FA dominated Lipids in the TBM, although there were significantly higher proportions of 16:0 (P = 0.000) and 22:6 n-3 (P=0.003) and lower proportions of 20:5n-3 (P=0.0072) in the TBM. A novel PUFA, 28:8n-3, was detected in both mussels with higher amounts in the TBM, which probably reflects a greater dietary contribution if dinoflagellates for this species. Cholesterol was the dominant sterol in both mussels. Other major sterols included brassicasterol, 22 methycholesterol, trans-22-dehydrocholesterol, and
Anti-inflammatory effects of stabilized lipid extract of Perna canaliculus (PCS-524™)

Georges M. Halpern, M.D., Ph.D., D.Sc. Professor Emeritus of Medicine, University of California, Davis Visiting Professor, The University of Hong Kong

Conclusion

PCSO-524™ is an extraordinary, and promising natural product. It is totally safe, easy to take, and does not impair the normal function of our organism. It demonstrates a gastro protective effect. Whereas most NSAIDs are gastro erosive. Contrary to fish oils, PCSO-524™ does not affect the thrombosis-associated system in normal individuals, i.e., does not promote bleeding.

It is remarkably active on the diverse components of inflammation, with specific cellular, mucosal, or joint targets. Much remains to be discovered and we are planning many studies addressing the too many ailments that make humans, even more the aging ones, suffer and complain.” It is the medicine of the future “(Micheal W. Whitehouse).

PCSO-524™: ANTI-INFLAMMATORY AND UTERINE-RELAXANT ACTIVITIES IN RATS, WITH SPECIAL REFERENCE TO A MODEL FOR DYSMENORRHEA

Summary

PCSO-524™ exhibits anti-inflammatory activity distinct from that of most NSAIDs, controlling chronic but not acute inflammation. Unlike Cox-1 inhibitors (aspirin, meclofenamic acid) it is not gastro-toxic. Predosing rats with PCSO-524™ can modify both (i) the spontaneous and (ii) the oxytocin-induced contractions of the uterus. In humans there is anecdotal evidence that PCSO-524™ can relieve dysmenorrhea. This report explores the concept that the uterotrophic actions of PCSO-524™ are conditioned by:

. the intrinsic profile of estrogenic hormones an progestagens and,

. certain extrinsic stimuli

Evidence from in vitro studies indicates that PCSO-524™ is not a smooth muscle relaxant and that its uterotrophic mechanism is not that of cyclo-oxygenase inhibitor, but may mimic that of a leukotriene receptor antagonist
ANTI-INFLAMMATORY ACTIVITY OF LIPID FRACTION (PCSO-524™) FROM THE NZ GREEN-LIPPED MUSSEL

M.W. WHITEHOUSE(1)*, T.A. MACRIDES(2), N. KALAFATIS(2), W.H. Betts(3), D.R. HAYNES(4) AND J. BROADBENT(5)

(1)Department of medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland 4102; (2) Department of Medical Laboratory Science, Royal Melbourne Institute of Technology, Victoria 3000; (3) Rheumatology, The Queen Elizabeth Hospital, Woodville, South Australia 5005; (5) McFarlane Laboratories, Surrey Hills, Victoria 3127, Australia

*Correspondence

ABSTRACT


A lipid-rich extract, prepared by supercritical fluid extraction of fresh stabilized mussel powder (PCSO-524™), showed significant anti-inflammatory (AI) activity given therapeutically and prophylactically to Wistar and Dark Agouti rats developing either (a) adjuvant-induced polyarthritis or (b) collagen(II)-induced autoallergic arthritis, with ED 50<15 mg/kg; cf naproxen > 25 mg/kg or various therapeutic oils (flaxseed, evening primrose, fish) > 1800 mg/kg given orally. PCSO-524™ showed little or no activity in acute irritation assays (carrageenan, kaolin, histamine) indicating it is not mimicking rapid-acting NSAIDs.

Incorporating PCSO-524™ into arthritigenic adjuvants composed of heat-killed Mycobacterium Tuberculosis suspended in olive oil or squalane, effectively prevented arthritis development at a dose of 5 mg/rat. By contrast, 'dummy adjuvants' prepared with Mycobacterium tuberculosis and flaxseed, evening primrose or fish oils were still arthritigenic in Dark Agouti rats (doses of oil = 90 mg/rat). PCSO-524™ subfractions inhibited leukotriene-B4 biosynthesis by stimulated human polymorphonuclear leukocytes in vitro, and prostaglandin-E(2) production by activated human macrophages in vitro. Much of this AI activity was associated with polyunsaturated fatty acids and natural antioxidants (carotenoids, etc.).

In contrast to NSAIDs PCSO-524™ is non-gastrotoxic in disease-stressed rats at 300 mg/kg po and does not seem to affect platelet aggregation (human, rat). These data show PCSO-524™ to be a reproducible, relatively stable, source of bioactive lipids with much greater potency than plant/marine oils currently used as nutritional supplements to ameliorate signs of inflammation.

Keywords: NZ green-lipped mussel, PCSO-524, lipid fraction, inflammation, NSAIDs
STEROID-SPARING ACTION OF PCSO-524™, A LIPID FRACTION FROM THE NZ GREEN-LIPPED MUSSEL (PCSO-524™).

M Whitehouse, Department of Medicine, Princess Alexandra Hospital, Woolloongabba, Qld 4102

Corticosteroids (CS) are powerful anti-inflammatory (AI) agents but their adverse effects on lymphoid and connective tissues largely restrict their clinical use. PCSO-524™ is a salt-free, non-allergenic AI nutriceutical that inhibits lipoxygenases and is not lympho-toxic (Whitehouse et al 1997). In one case of asthma, PCSO-524™ ingestion reduced prednisone requirement by 80% (Harbison a Whitehouse 2000), suggesting a synergistic effect of CS with PCSO-524™. This possible synergy was examined using rat models of chronic inflammation initiated by three clinically relevant pathogenic irritants namely yeast cell wall (zymosan 0.5 mg), silica (4 mg), and calcium pyrophosphate (causing pseudo gout, 7 mg), each injected in 0.2 ml saline/rat paw. After three hours animals were dosed orally and daily thereafter for four days. Drug efficacy/toxicity was assessed by a) changes in paw thickness and body weight measured daily and b) size of spleen and thymus (day 5) and susceptibility to gastric bleeding from NSAIDs (60 mg/kg ibuprofen po or 5 mg/kg piroxicm ip) given on day 5 after fasting overnight. Prednisone (P) and dexamethasone (D) used singly gave ED50s for reducing paw swelling (after 48 hours) of approximately 6 mg/kg and 0.5 mg/kg, respectively, with massive thymus involution (>90%) and considerable NSAID-gastropathy, compared to non CS-treated inflamed rats. By contrast, repeated dosing with aspirin (300 mg/kg), ibuprofen (60 mg/kg), naproxen, Celebrex and Vioxx (all at 25 mg/kg) had almost no effect on persisting paw swelling. Minimally effective (< ED20) CS doses of 3 mg/kg P or 0.1 mg/kg D given alone now became >ED70 doses when co-administered with PCSO-524™ 13 mg/kg, zafirlukast 20 mg/kg) were not able to replace PCSO-524™ in these rat studies. Commercial extracts of whole green mussel (Perna canaliculus from MacLab Australia) 260 mg/kg also acted synergistically with P and D but similar extracts from NZ-sourced blue mussel (Mytulis edulis) did not. These data confirm that the lipoxygenase-inhibiting and other AI properties of PCSO-524™ allow considerable reduction of CS dosage when used concurrently to treat chronic/fibrogenic inflammation.


Inflammaoparmacol, 5,237-246

THE MARINE OIL, PCSO-524™ IS A SUBSTRATE FOR THE 5-LIP 资

S Mc (1), N Kalafatis (1), PFA Wright (2) and TA Macrides (1), (1) Natural Products Unit, (2) Toxicology Unit, School of Medical Sciences, RMIT Univ, Bundoora, Vic 3083

PCSO-524™ is the supercritical fluid oil extract of the New Zealand green-lipped mussel, Perna canaliculus. PCSO-524™ inhibits the production by human neutrophils of leukotriene B(4) (LTB(4)), a significant metabolite of the 5-
lipoxygenase (5-LO) enzyme pathway, and has also exhibited anti-inflammatory effects in animal models of arthritis (Whitehouse et al 1997). This study in Porcine neutrophils investigates the inhibition of LTB(4), its isomers (6-trans LTB(4) and 6-trans-12-epi LTB(4)) and 5-hydroxyeicosatetraenoic acid (5-HETE) as well as following the production of PCSO-524™-derived 5-LO metabolites. Porcine neutrophils (2.6 x 10(6) cell/ml) were isolated on a percoll gradient and preincubated (37°C) with various concentrations of PCSO-524™ (10, 3.3, 1.0, 0.33, 0.1 μg/ml) before addition of arachidonis acid (AA) substrate (2.5μM). The 5-LO pathway was initiated by the addition of calcium ionophore A23187 (2.5μM) and incubated for 5 min. The 5-LO metabolites were identified by comparison of retention times with known standards and quantified against internal standards (prostaglandin B(2) and 15-HETE) by HPLC with photodiode array detection at 270nm (LT’s) and 235nm (HETE’s). PCSO-524™ (10μg/ml) inhibited the production of LTB(4) by 72.2 _+1.9%, 6-trans LTB(4) by 47.3 _+2.2%, 6-trans-12epi LTB(4) by 39.0 _+2.1% and 5-HETE by 19.6 _+ 8.7% (n=4), when compared to the vehicle control. PCSO-524™ itself contains eicosapentaenoic acid (EPA) which the neutrophils converted to similar amounts of LTB(5) and 5-hydroxyeicosapentaenoic acid (5-HEPE) both in the presence or absence of exogenous AA. Other ‘leukotriene-like’ Peaks exhibiting the characteristic triene chromophore were also produced, but remain unidentified. Therefore in addition to PCSO-524™’s inhibition of the production of proinflammatory LTB(4), this study has shown that omega-3 polyunsaturated fatty acids present in PCSO-524™ are substrates for 5-LO. This may contribute to PCSO-524™ beneficial effects, as the metabolites are expected to be less proinflammatory than AA metabolites.


Treating inflammation: some (needless) difficulties for gaining acceptance of effective natural products and traditional medicines

D.E.. BUTTERS* and M W. WHITEHOUSE
Therapeutics Research Unit, Dept. of Medicine, University of Queensland. Princess Alexandra Hospital, Woolloongabba. QLD 4102, Australia

Received 29 July 2002; revised 30 September 2002; accepted 3 October 2002

Abstract- The quality of so-called ‘natural medicines’ is extraordinarily variable. Lack of resolute pharmacological assays contributes to this hiatus. More stringent evaluation of anti-inflammatory and anti-pyretic activities in rats can help resolve some of the uncertainties surrounding (a) preparations of some herbal products including so-called nature’s aspirin (eg, willowbark, ginger), cat’s claw, celery seed etc, and (b) some animal lipids (eg. Lyprinol® (NZ
mussel), emu and fish oils) These animal products can be a remarkable resource for supplementing conventional/allopathic therapy for inflammatory disease, e.g. providing lipoxynase inhibitors. Beyond the verifiable science, the healing professions and the general public still need to examine more carefully criteria for QUALITY(S) in any alternative medicine-to ensure the good (=both reputations and products) are not destroyed by the bad-in essence counteracting Gresham’s Law which states: the bad tends to displace the good.

**Marine lipid fraction PCSO-524_ (lyprinol_/omega XL_) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma.**

Timothy D. Mickleborough*, Cherissa L. Vaughn, Ren-Jay Shei, Eliza M. Davis, Daniel P. Wilhite School of Public Health-Bloomington, Department of Kinesiology, Human Performance and Exercise.

**Biochemistry Laboratory, 1025 E. 7th St. SPH 112, Bloomington, IN 47404, USA**

**Summary**

**Purpose:** Evaluate the effect of the marine lipid fraction of the New Zealand green-lipped mussel (Perna canaliculus) PCSO-524_ (Lyprinol_/Omega XL_), rich in omega-3 fatty acids, on airway inflammation and the bronchoconstrictor response to eucapnic voluntary hyperpnea (EVH) in asthmatics.

**Methods:** Twenty asthmatic subjects, with documented HIB, participated in a placebo controlled double-blind randomized crossover trial. Subjects entered the study on their usual diet and were then placed on 3 weeks of PCSO-524_ or placebo supplementation, followed by a 2 week washout period, before crossing over to the alternative diet.

Pre- and post-eucapnic voluntary hyperpnea (EVH) pulmonary function, fraction of exhaled nitric oxide (FENO), asthma symptom scores, medication use, exhaled breath condensate (EBC) pH, cysteinyll leukotrienes (cyst-LT), 8-isoprostan and urinary 9a, 11b-prostaglandin (PG)F2 and Clara (CC16) protein concentrations were assessed at the beginning of the trial and at the end of each treatment period.

**Results:** The PCSO-524_ diet significantly reduced (p < 0.05) the maximum fall in post-EVH FEV1 (_8.4 _ 3.2%) compared to usual (_19.3 _ 5.4%) and placebo diet (_22.5 _ 13.7%).

**Pre- and post-EVH EBC cyst-LT and 8-isoprostan, and urinary 9a, 11b-PGF2 and CC16 concentrations were significantly reduced (p < 0.05) on the PCSO-524_ diet compared to the usual and placebo diet. EBC pH and asthma symptom scores were significantly improved (p < 0.05) and rescue medication use significantly reduced (p < 0.05) on the PCSO-524_ diet compared to the usual and placebo diet.
Marine oil dietary supplementation reduces delayed onset muscle soreness after a 30 km run.

**Objective:** Runners are prone to delayed onset muscle soreness (DOMS) during long distance training. This especially holds for unaccustomed training volumes at moderate to high intensities. We investigated the effects of a marine oil complex, PCSO-524®, derived from the New Zealand green-lipped mussel (formulated as Lyprinol® and Omega XL®) on DOMS after a 30 km training run.

**Methods:** Initially, peak oxygen uptake of 32 distance runners (4 female, 28 male; median age 45 years, range 28–53) was measured on a treadmill with a 1.5 km hour⁻¹ increase every 4 minutes starting from 8.5 km hour⁻¹. At least 1-week after this initial test, they participated in a 30 km road run at a speed corresponding to about 70% of their individual peak oxygen uptake on a flat terrain. Before and after (0, 24, and 48 hours) the run, blood concentration of creatine kinase (CK) were measured and pain sensation was determined (pain scale from 0 = no pain to 10 = extremely painful). Runners were then matched in pairs based on maximal CK and peak oxygen uptake, and allocated randomly into two different groups. One group was supplemented with 400 mg per day of PCSO-524® for 11 weeks, the other group with an olive oil placebo. After that period, CK and pain sensations were remeasured following a second 30 km run at the same speed and on the same terrain.

**Results:** The general pattern of soreness in the PCSO-524® supplemented group was reduced by 1.1 units (standard error 0.41) compared to the placebo ($P < 0.05$), the effects being greater in lesser trained runners ($P < 0.05$). CK levels were positively associated with pain sensation ($P < 0.05$), but trends toward lower CK in the PCSO-524® group, which were also more pronounced in the lesser trained runners, were not statistically significant.

**Conclusion:** Pain sensations experienced by distance runners following a 30 km run were reduced by supplementation with the marine oil complex PCSO-524®, an effect which was greater in lesser trained runners.

**Keywords:** Running, marine oil, DOMS, creatine kinase.
TREATMENT OF CHILDREN’S ASTHMA WITH A LIPID EXTRACT OF THE NEW ZEALAND GREEN LIPPED MUSSEL (PERNA CANALICULUS) (LYPRINOL®) - A DOUBLE BLIND, RANDOMISED CONTROLLED TRIAL IN CHILDREN WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE ASTHMA.

James Lello, A Liang, E Robinson, D Leutenegger, A Wheat
(1) Asthma New Zealand The Lung Association (Inc.), Department of Clinical Trials, Auckland, New Zealand
(2) Paediatric Allergy Specialist, St Heliers, Auckland, New Zealand
(3) University of Auckland, Medical and Health Science Campus (Tamaki), Department of Community Health, Auckland, New Zealand
(4) University of Auckland, Medical and Health Science Campus (Tamaki), Department of General Practice and Primary Healthcare, Auckland, New Zealand
(5) Marsden Medical Ltd., Auckland, New Zealand

Shellfish are rich in the omega-3 fatty acid eicosapentaenoic acid (EPA). EPA may potentially act to reduce airway inflammation and bronchoconstriction. The efficacy and safety of an oral standardised lipid extract of New Zealand green lipped mussel (Perna canaliculus) marketed as Lyprinol® was assessed as maintenance therapy for children with asthma.

A total of 71 children aged 6 to 13 years were enrolled in a 16-week, single centre, double masked, placebo controlled, parallel-group trial and randomly assigned to receive either Lyprinol® or placebo (2 capsules twice daily). Patients were maintained on inhaled corticosteroid (ICS) and as-needed β-agonist therapy throughout the study. If stable at monthly study visits ICS dose was reduced by 25%. Safety monitoring included end-tidal breath nitric oxide measurement. Primary outcome measures were inhaled corticosteroid dose reduction with secondary outcome measures of asthma exacerbation rate, asthma symptom score, Juniper quality of life score and use of short acting β-agonist. Lyprinol® improved the percentage of children reporting little or no trouble with their asthma at three months of treatment (97% vs. 76% p < 0.06). Both groups were able to tolerate a dose reduction of ICS with no significant difference between placebo and Lyprinol® group. There were fewer mild and moderate asthma exacerbations overall in the Lyprinol® group. Lyprinol® was well tolerated. We conclude that Lyprinol® is a safe nutritional supplement taken by children with moderate asthma and that larger prospective controlled studies should explore its potential use as an addition to conventional treatment.